$11.428
-0.247 (-2.16%)At close
INKT Comparative Benchmarking
In the context of the broader market, INKT competes directly with industry leaders such as IMA and ELOX. With a market capitalization of $57.51M, it holds a significant position in the sector. When comparing efficiency, INKT's gross margin of N/A stands against IMA's N/A and ELOX's N/A. Such benchmarking helps identify whether Mink Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Mink Therapeutics Inc Financial Performance
The company has been experiencing significant net losses, with Q2 2026 net loss at $3.1 million and a consistent negative EPS trend, with the latest at -0.62. The current ratio is 1.23, indicating some liquidity, but overall financial health appears weak.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.